Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| 5-Amino-1MQ | BPC-157 (Oral Stable Form) | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 50-150 mg daily via oral administration, typically divided into 1-2 doses. | Research indicates 250-500 mcg twice daily via oral capsule on empty stomach. |
| Timing | Morning dosing preferred. Can be taken with or without food. | On empty stomach, 30 minutes before meals. Twice daily dosing (morning and evening) provides consistent levels. |
| Cycle Duration | 8-12 week cycles. | 4-12 weeks. Oral form enables easier long-term use compared to injectable. |
| Evidence Level | animal_plus_anecdotal | animal_plus_anecdotal |
5-Amino-1MQ is a small molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that catalyzes the transfer of a methyl group from S-adenosylmethionine (SAM) to nicotinamide, generating 1-methylnicotinamide (1-MNA). By inhibiting NNMT, 5-Amino-1MQ increases intracellular NAD+ levels, reduces 1-MNA production, suppresses lipogenesis in adipocytes, and modulates the methionine-homocysteine cycle. In vivo, it significantly reduces body weight, white adipose mass, and adipocyte size through enhanced energy expenditure and altered lipid metabolism.
Research indicates 50-150 mg daily via oral administration, typically divided into 1-2 doses.
Morning dosing preferred. Can be taken with or without food.
8-12 week cycles.
Oral-stable BPC-157, typically formulated as the arginate salt, retains the same mechanism as standard BPC-157 — promoting angiogenesis via VEGFR2/PI3K/Akt/eNOS and Src-Caveolin-1-eNOS pathways, enhancing nitric oxide production, and stimulating tendon fibroblast growth and collagen formation. The arginate salt provides a protective buffer against gastric acid degradation, maintaining peptide integrity across a wider pH range. BPC-157 demonstrates remarkable native stability in human gastric juice (24+ hours), and the arginate form reportedly achieves 7-fold greater oral bioavailability compared to the acetate salt in preclinical studies.
Research indicates 250-500 mcg twice daily via oral capsule on empty stomach.
On empty stomach, 30 minutes before meals. Twice daily dosing (morning and evening) provides consistent levels.
4-12 weeks. Oral form enables easier long-term use compared to injectable.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →